Pulmonx (LUNG) to Release Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) will issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.02. Pulmonx had a negative net margin of 88.60% and a negative return on equity of 46.63%. The company had revenue of $19.30 million during the quarter, compared to the consensus estimate of $18.24 million. During the same quarter last year, the firm posted ($0.38) EPS. The company’s quarterly revenue was up 25.3% on a year-over-year basis. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulmonx Stock Up 1.4 %

Pulmonx stock opened at $7.50 on Wednesday. The company has a market capitalization of $289.05 million, a PE ratio of -4.69 and a beta of 0.60. Pulmonx has a 12-month low of $7.21 and a 12-month high of $14.84. The firm’s fifty day moving average is $9.49 and its 200 day moving average is $10.77. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30.

Wall Street Analysts Forecast Growth

LUNG has been the topic of several research reports. Piper Sandler reiterated an “overweight” rating and set a $17.00 price objective on shares of Pulmonx in a report on Wednesday, April 3rd. Citigroup upped their price target on Pulmonx from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Stifel Nicolaus raised their price objective on Pulmonx from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $14.00 price objective (down previously from $16.00) on shares of Pulmonx in a report on Friday, February 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.83.

Insider Buying and Selling

In other Pulmonx news, CEO Glendon E. French III sold 6,954 shares of Pulmonx stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $63,003.24. Following the completion of the transaction, the chief executive officer now owns 1,116,758 shares in the company, valued at approximately $10,117,827.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Glendon E. French III sold 6,954 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $9.06, for a total value of $63,003.24. Following the completion of the sale, the chief executive officer now directly owns 1,116,758 shares of the company’s stock, valued at approximately $10,117,827.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.60, for a total value of $292,000.00. Following the transaction, the chief executive officer now owns 1,121,344 shares in the company, valued at $16,371,622.40. The disclosure for this sale can be found here. Insiders have sold 37,848 shares of company stock worth $460,144 in the last quarter. Insiders own 5.70% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.